Publications by authors named "Philippe Ferber"

Claim this Profile
O
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.
Antonio M Risitano, Austin G Kulasekararaj, Phillip Scheinberg, Alexander Röth, Bing Han, Philippe Ferber

Lancet Haematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity.
David M Leistner, Andres Laguna-Fernandez, Arash Haghikia, Youssef S Abdelwahed, Anne-Sophie Schatz, Philippe Ferber

Eur J Prev Cardiol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank.
Paul Welsh, Anas Al Zabiby, Hannah Byrne, Harriet R Benbow, Taha Itani, Philippe Ferber

Atherosclerosis· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States.
Ana F Fonseca, Hannah Byrne, Andres Laguna, Taha Itani, Rachel Studer, Philippe Ferber

J Manag Care Spec Pharm· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.
Lars H Lund, Uwe Zeymer, Andrew L Clark, Vivencio Barrios, Thibaud Damy, Philippe C Ferber

Int J Cardiol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry.
Aldo P Maggioni, Andrew L Clark, Vivencio Barrios, Thibaud Damy, Jaroslaw Drozdz, Philippe C Ferber

ESC Heart Fail· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
Uwe Zeymer, Andrew L Clark, Vivencio Barrios, Thibaud Damy, Jaroslaw Drożdż, Philippe C Ferber

Eur Heart J Qual Care Clin Outcomes· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study.
Fd Richard Hobbs, Rizwan I Hussain, Cristina Vitale, Yigal M Pinto, Hector Bueno, Philippe C Ferber

Open Heart· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
Massimo F Piepoli, Rizwan I Hussain, Josep Comin-Colet, Ramon Dosantos, Philippe Ferber

Eur J Heart Fail· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
Katrijn Bogman, Dietmar Schwab, Marie-Laure Delporte, Giuseppe Palermo, Kurt Amrein, Philippe Ferber

Hypertension· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers for cardiovascular risk assessment in autoimmune diseases.
Priscila Camillo Teixeira, Philippe Ferber, Nicolas Vuilleumier, Paul Cutler

Proteomics Clin Appl· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases.
Priscila Camillo Teixeira, Axel Ducret, Philippe Ferber, Hubert Gaertner, Oliver Hartley

J Biol Chem· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.
Dion Zappe, Cheraz Cherif Papst, Philippe Ferber,

Vasc Health Risk Manag· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
Lars-Christian Rump, Elena Baranova, Boguslaw Okopien, Marianne Weisskopf, Albert Kandra, Philippe Ferber

Clin Ther· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
Janaka Karalliedde, Andrew Smith, Lorenita DeAngelis, Vincenzo Mirenda, Albert Kandra, Philippe Ferber

Hypertension· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public health value of fixed-dose combinations in hypertension.
Luis M Ruilope, Michel Burnier, Noemi Muszbek, Ruth E Brown, Abdulkadir Keskinaslan, Philippe Ferber

Blood Press Suppl· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy.
Jaakko Tuomilehto, Andrzej Tykarski, Peter Baumgart, Bernard Reimund, Stephanie Le Breton, Philippe Ferber

Blood Press Suppl· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
Yves Allemann, Belen Fraile, Michel Lambert, Michaela Barbier, Philippe Ferber

J Clin Hypertens (Greenwich)· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal antibodies: Comparative methods for in vitro production.
René W. Fischer, Philippe C. Ferber

ALTEX· January 1992

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis